Archemesis.

If you read the latest ASCO guidelines on antiemetics and thought: “What the heck is an NK1 receptor antagonist..?” then this one’s for you. This Chinese double-blind phase 3 trial assessed the efficacy of adding the NK1 inhibitor aprepitant to more established antiemetics in women receiving FOLFOX or FOLFIRI for gastric cancer. The other antiemetics everyone received were dex and palonosetron (a serotonin inhibitor like ondansetron). The primary endpoint of complete antiemetic response, defined as having neither vomiting nor need for further antiemetics, was achieved by significantly more women receiving aprepitant (87%) than the controls (67%). | Wang, JAMA Netw Open 2021